FOR
IMDX

Family Office Research’s Insight Molecular Diagnostics IMDX Stock Holding History

Family Office Research’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Buy
368,849
+241,583
+190% +$1.19M 0.82% 22
2026
Q1 		$417K Buy
+127,266
New +$739K 0.18% 51

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Family Office Research's IMDX Position: Q2 2026 in Review

Family Office Research increased its Insight Molecular Diagnostics (IMDX) stake by 190% in Q2 2026, buying an estimated $1.19M and bringing the position to 368,849 shares worth $2.18M. The position accounts for 0.82% of the portfolio, ranked #22.

Family Office Research first reported a position in IMDX in Q1 2026 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Family Office Research held 368,849 shares of Insight Molecular Diagnostics worth $2.18M as of Q2 2026.
  • Family Office Research bought 241,583 Insight Molecular Diagnostics shares in Q2 2026, an estimated $1.19M.
  • Insight Molecular Diagnostics made up 0.82% of Family Office Research's portfolio in Q2 2026, its #22 holding.
  • Family Office Research first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Family Office Research's 13F filing for Q2 2026, filed 27 Jul 2026.